On Oct. 20, 2020, BioReference Laboratories, an OPKO Health company, announced that it was accepting specimens for a new multiplex COVID-19 and influenza test for use by healthcare providers, clinics and health systems throughout the U.S., to aid in the diagnosis of COVID-19 and Influenza A or B (flu).